Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782064 | 0.92 | LMNA (0.55) | ABL1RIN1ALDH1A1MEN1KMT2A | |
| SCHEMBL26017418 | 0.90 | ABL1 (0.53) | ABL1RIN1ALDH1A1MEN1KMT2A | |
| SCHEMBL1008089 | 0.89 | ALDH1A1 (0.49) | ABL1RIN1ALDH1A1MEN1KMT2A | |
| SCHEMBL12191688 | 0.89 | L3MBTL1 (0.50) | ABL1RIN1ALDH1A1MEN1KMT2A | |
| SCHEMBL31594790 | 0.89 | ALDH1A1 (0.49) | ABL1RIN1ALDH1A1MEN1KMT2A | |
| SCHEMBL2391813 | 0.88 | ALDH1A1 (0.53) | ABL1RIN1ALDH1A1MEN1KMT2A | |
| SCHEMBL14336130 | 0.88 | HSD17B10 (0.55) | ABL1RIN1ALDH1A1MEN1KMT2A | |
| SCHEMBL3229106 | 0.87 | ALDH1A1 (0.48) | ABL1RIN1ALDH1A1MEN1KMT2A | |
| SCHEMBL30038050 | 0.87 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ALMNAMAPK1 | |
| SCHEMBL2002022 | 0.87 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20240366552-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2024-11-07 | — | — | US | disclosed |
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2024-04-11 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2023-08-17 | — | — | US | disclosed |
| US-4250181-A | HYPOTENSIVE AGENTS, ANTIDEPRESSANTS | THE UPJOHN COMPANY (US) | 1981-02-10 | — | — | US | disclosed |
| US-4250175-A | HYPOTENSIVE AGENTS, ANTIDEPRESSANTS | PHARMACIA & UPJOHN COMPANY | 1981-02-10 | — | — | US | disclosed |
| US-4247553-A | HYPOTENSIVE AGENTS, ANTIDEPRESSANTS | THE UPJOHN COMPANY (US) | 1981-01-27 | — | — | US | disclosed |
| US-4221788-A | 2-(Optionally-substituted)benzylperhydroazepines for analgesia and lowering blood pressure | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1980-09-09 | — | — | US | disclosed |
| US-4207239-A | HYPOTENSIVE, ANTIPSYCHOTIC | THE UPJOHN COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
| US-4206123-A | INTERMEDIATES FOR HYPOTENSIVES | MCCALL JOHN M (US) | 1980-06-03 | — | — | US | disclosed |
| US-4181665-A | INTERMEDIATES FOR AMINO DERIVATIVES POSSESSING HYPOTENSIVE AND CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1980-01-01 | — | — | US | disclosed |
| US-4179510-A | ISOCHROMANS AND 2-BENZOXEPINS | THE UPJOHN COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| US-4166062-A | HYPOTENSIVE AGENTS, CNS, ANTIDEPRESSANTS | THE UPJOHN COMPANY (US) | 1979-08-28 | — | — | US | disclosed |
| US-4153612-A | 2-Benzoxepins | THE UPJOHN COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | ABL1 3564/4885RIN1 2683/4885ALDH1A1 1088/4885 |
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | ABL1 1470/4885RIN1 4325/4885ALDH1A1 3189/4885 |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | ABL1 1470/4885RIN1 4325/4885ALDH1A1 3189/4885 |
| US-20240366552-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | ABL1 1470/4885RIN1 4325/4885ALDH1A1 3189/4885 |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | ABL1 1470/4885RIN1 4325/4885ALDH1A1 3189/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | ABL1 3389/4885RIN1 3246/4885ALDH1A1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.